Hyperion Therapeutics Inc (HPTX) 26.83 $HPTX
Hyperion Therapeutics Initiates Clinical Study to Further Evaluate RAVICTI(R) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders
GlobeNewswire - Tue Feb 10, 8:07AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the dosing of the first patient in its HPN-100-009 study in pediatric subjects under two years of age with urea cycle disorders (UCDs). This open-label study and post-marketing requirement is designed to assess the efficacy, safety and pharmacokinetics of RAVICTI and will enroll UCD patients who are newly diagnosed or being switched from sodium phenylbutyrate. Hyperion estimates that patients in the first two years of life account for 15-20% of all patients diagnosed with UCDs and approximately 10% of the total volume of phenylbutyrate used in the U.S.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 2:40 p.m. EST. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Insider Trading Alert - PETS, HPTX And OPTT Traded By Insiders
at The Street - Fri Jan 23, 10:00AM CST
Stocks with insider trader activity include PETS, HPTX and OPTT
OPTT: 0.50 (-0.02), PETS: 15.57 (-0.05), HPTX: 26.83 (-0.05)
Hyperion Therapeutics Announces Data Published in Genetics in Medicine Showing Blood Ammonia and Glutamine as Predictors of Hyperammonemic Crises in Patients With Urea Cycle Disorders
GlobeNewswire - Mon Jan 12, 8:25AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the online publication in Genetics in Medicine of analyses from four short-term switchover (SO) studies and three 12-month safety extension studies examining the relationships between fasting ammonia, daily ammonia exposure, and hyperammonemic crises (HAC) in adult and pediatric patients with urea cycle disorders (UCD.) The article titled "Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder," is available online at http://www.nature.com/gim/journal/vaop/ncurre...4148a.html.
HPTX: 26.83 (-0.05)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), HPTX: 26.83 (-0.05)
Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI)
GlobeNewswire - Thu Dec 18, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:NBI). The semi-annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), HPTX: 26.83 (-0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Hyperion Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Thu Dec 04, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference on Thursday, December 11, 2014, at 9:10 a.m. EST. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics (HPTX) Downgraded From Hold to Sell
at The Street - Fri Nov 14, 8:37AM CST
Hyperion Therapeutics (HPTX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference
GlobeNewswire - Thu Nov 13, 3:09PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Jefferies 2014 Global London Healthcare Conference on Thursday, November 20, 2014, at 1:00 p.m. GMT. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics' (HPTX) CEO Don Santel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 4:17AM CST
HPTX: 26.83 (-0.05)
Hyperion tops 3Q revenue forecasts
Automated Insights - Thu Nov 06, 5:37PM CST
BRISBANE, Calif. (AP) _ Hyperion Therapeutics Inc. (HPTX) on Thursday reported a loss of $32.8 million in its third quarter.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics beats by $0.18, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:41PM CST
HPTX: 26.83 (-0.05)
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:00PM CST
-- UCD Product Portfolio Generates $26.2 Million in Net Sales During the Quarter --
HPTX: 26.83 (-0.05)
Hepatic Encephalopathy Therapeutics Pipeline Review 2014 - 4 Companies & 5 Drug Profiles
M2 - Thu Nov 06, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/pccbnw/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Alfa Wassermann S.p.A - Umecrine Cognition AB Drug Profiles - rifaximin - glycerol phenylbutyrate - ornithine phenylacetate - THDP-17 - CVXL-0060 For more information visit http://www.researchandmarkets.com/research/pccbnw/hepatic
OCRX: 6.27 (-0.16), HPTX: 26.83 (-0.05)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 3.90 (+0.01), ACET: 20.00 (+0.27), ANET: 62.93 (+1.94), FNGN: 39.76 (+0.11), CPST: 0.73 (+0.03), AUQ: 3.58 (-0.03), AMRN: 1.18 (unch), ED: 63.92 (-1.69), ENV: 54.13 (-0.19), FXCM: 2.21 (-0.01), BCEI: 28.74 (+0.16), GXP: 26.77 (-0.60), EAC: 7.19 (+0.13), DXCM: 62.68 (+0.74), CSC: 66.10 (+1.60), AEL: 29.15 (+0.66), HNSN: 1.05 (+0.02), CFN: 59.81 (+0.01), ANAC: 40.76 (-0.07), DAR: 17.29 (-0.01), GST: 2.89 (unch), ARC: 9.37 (-0.07), FIVN: 3.78 (-0.09), ELON: 1.16 (-0.01), FSLR: 48.84 (-0.58), EZPW: 9.96 (-0.29), ALIM: 5.16 (unch), FWM: 5.55 (+0.08), BRS: 61.71 (+3.65), ECOM: 9.69 (+0.63), FTEK: 3.31 (+0.01), CVT: 28.33 (+1.52), AL: 38.65 (+0.27), BBRG: 13.49 (-0.01), BPZ: 0.25 (unch), ECPG: 41.44 (+0.51), HTGC: 15.49 (+0.04), AIRM: 45.33 (+0.24), BNFT: 21.08 (+0.84), ENOC: 18.24 (+0.22), HPTX: 26.83 (-0.05), AGO: 26.41 (+0.15), FICO: 82.00 (+1.50), FF: 12.10 (+0.41), FI: 16.35 (+0.12), EVC: 7.09 (-0.07), EBS: 28.76 (-0.12), ABCO: 53.69 (+0.32), DIOD: 27.81 (-0.32), DIS: 104.17 (+0.59), EGOV: 16.20 (+0.30), APEI: 34.36 (-0.08), DVA: 73.10 (-3.29), CLVS: 68.79 (+0.71), HCI: 50.01 (+0.71), BRKR: 18.77 (-0.02), HGR: 22.98 (+0.15)
Hyperion Therapeutics (HPTX) Downgraded From Buy to Hold
at The Street - Tue Nov 04, 8:21AM CST
Hyperion Therapeutics (HPTX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6, 2014
GlobeNewswire - Fri Oct 31, 8:00AM CDT
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report third quarter 2014 financial results after market close on Thursday, November 6, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update at 4:05 p.m. ET (1:05 p.m. PT).
HPTX: 26.83 (-0.05)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 16.96 (unch), UTHR: 151.11 (+3.59), PCRX: 113.94 (-0.91), HPTX: 26.83 (-0.05)
Hyperion Therapeutics Initiates Clinical Study to Further Evaluate RAVICTI(R) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders
GlobeNewswire - Tue Feb 10, 8:07AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the dosing of the first patient in its HPN-100-009 study in pediatric subjects under two years of age with urea cycle disorders (UCDs). This open-label study and post-marketing requirement is designed to assess the efficacy, safety and pharmacokinetics of RAVICTI and will enroll UCD patients who are newly diagnosed or being switched from sodium phenylbutyrate. Hyperion estimates that patients in the first two years of life account for 15-20% of all patients diagnosed with UCDs and approximately 10% of the total volume of phenylbutyrate used in the U.S.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 2:40 p.m. EST. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Insider Trading Alert - PETS, HPTX And OPTT Traded By Insiders
at The Street - Fri Jan 23, 10:00AM CST
Stocks with insider trader activity include PETS, HPTX and OPTT
OPTT: 0.50 (-0.02), PETS: 15.57 (-0.05), HPTX: 26.83 (-0.05)
Hyperion Therapeutics Announces Data Published in Genetics in Medicine Showing Blood Ammonia and Glutamine as Predictors of Hyperammonemic Crises in Patients With Urea Cycle Disorders
GlobeNewswire - Mon Jan 12, 8:25AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the online publication in Genetics in Medicine of analyses from four short-term switchover (SO) studies and three 12-month safety extension studies examining the relationships between fasting ammonia, daily ammonia exposure, and hyperammonemic crises (HAC) in adult and pediatric patients with urea cycle disorders (UCD.) The article titled "Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder," is available online at http://www.nature.com/gim/journal/vaop/ncurre...4148a.html.
HPTX: 26.83 (-0.05)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), HPTX: 26.83 (-0.05)
Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI)
GlobeNewswire - Thu Dec 18, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:NBI). The semi-annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), HPTX: 26.83 (-0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Hyperion Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Thu Dec 04, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference on Thursday, December 11, 2014, at 9:10 a.m. EST. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics (HPTX) Downgraded From Hold to Sell
at The Street - Fri Nov 14, 8:37AM CST
Hyperion Therapeutics (HPTX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference
GlobeNewswire - Thu Nov 13, 3:09PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Jefferies 2014 Global London Healthcare Conference on Thursday, November 20, 2014, at 1:00 p.m. GMT. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics' (HPTX) CEO Don Santel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 4:17AM CST
HPTX: 26.83 (-0.05)
Hyperion tops 3Q revenue forecasts
Automated Insights - Thu Nov 06, 5:37PM CST
BRISBANE, Calif. (AP) _ Hyperion Therapeutics Inc. (HPTX) on Thursday reported a loss of $32.8 million in its third quarter.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics beats by $0.18, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:41PM CST
HPTX: 26.83 (-0.05)
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:00PM CST
-- UCD Product Portfolio Generates $26.2 Million in Net Sales During the Quarter --
HPTX: 26.83 (-0.05)
Hepatic Encephalopathy Therapeutics Pipeline Review 2014 - 4 Companies & 5 Drug Profiles
M2 - Thu Nov 06, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/pccbnw/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Alfa Wassermann S.p.A - Umecrine Cognition AB Drug Profiles - rifaximin - glycerol phenylbutyrate - ornithine phenylacetate - THDP-17 - CVXL-0060 For more information visit http://www.researchandmarkets.com/research/pccbnw/hepatic
OCRX: 6.27 (-0.16), HPTX: 26.83 (-0.05)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 3.90 (+0.01), ACET: 20.00 (+0.27), ANET: 62.93 (+1.94), FNGN: 39.76 (+0.11), CPST: 0.73 (+0.03), AUQ: 3.58 (-0.03), AMRN: 1.18 (unch), ED: 63.92 (-1.69), ENV: 54.13 (-0.19), FXCM: 2.21 (-0.01), BCEI: 28.74 (+0.16), GXP: 26.77 (-0.60), EAC: 7.19 (+0.13), DXCM: 62.68 (+0.74), CSC: 66.10 (+1.60), AEL: 29.15 (+0.66), HNSN: 1.05 (+0.02), CFN: 59.81 (+0.01), ANAC: 40.76 (-0.07), DAR: 17.29 (-0.01), GST: 2.89 (unch), ARC: 9.37 (-0.07), FIVN: 3.78 (-0.09), ELON: 1.16 (-0.01), FSLR: 48.84 (-0.58), EZPW: 9.96 (-0.29), ALIM: 5.16 (unch), FWM: 5.55 (+0.08), BRS: 61.71 (+3.65), ECOM: 9.69 (+0.63), FTEK: 3.31 (+0.01), CVT: 28.33 (+1.52), AL: 38.65 (+0.27), BBRG: 13.49 (-0.01), BPZ: 0.25 (unch), ECPG: 41.44 (+0.51), HTGC: 15.49 (+0.04), AIRM: 45.33 (+0.24), BNFT: 21.08 (+0.84), ENOC: 18.24 (+0.22), HPTX: 26.83 (-0.05), AGO: 26.41 (+0.15), FICO: 82.00 (+1.50), FF: 12.10 (+0.41), FI: 16.35 (+0.12), EVC: 7.09 (-0.07), EBS: 28.76 (-0.12), ABCO: 53.69 (+0.32), DIOD: 27.81 (-0.32), DIS: 104.17 (+0.59), EGOV: 16.20 (+0.30), APEI: 34.36 (-0.08), DVA: 73.10 (-3.29), CLVS: 68.79 (+0.71), HCI: 50.01 (+0.71), BRKR: 18.77 (-0.02), HGR: 22.98 (+0.15)
Hyperion Therapeutics (HPTX) Downgraded From Buy to Hold
at The Street - Tue Nov 04, 8:21AM CST
Hyperion Therapeutics (HPTX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C.
HPTX: 26.83 (-0.05)
Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6, 2014
GlobeNewswire - Fri Oct 31, 8:00AM CDT
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report third quarter 2014 financial results after market close on Thursday, November 6, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update at 4:05 p.m. ET (1:05 p.m. PT).
HPTX: 26.83 (-0.05)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 16.96 (unch), UTHR: 151.11 (+3.59), PCRX: 113.94 (-0.91), HPTX: 26.83 (-0.05)
